Invitrogen and the Human Proteome Organisation Enter Protein Research Scientific Partnership; Groups Will Further HUPO Scientific Initiatives, Enable Standardization of Research Processes.

CARLSBAD, Calif. -- Invitrogen Corporation (Nasdaq:IVGN) and the Human Proteome Organisation (HUPO) have entered a scientific collaboration focused on advancing proteomic research through education initiatives, standardization of research protocols and development of advanced proteomic products. Under the terms of the collaboration, Invitrogen scientists will support efforts driven by HUPO and its members internationally to develop new proteomic standards, products and processes. Invitrogen will also support a number of global educational programs and resources. Financial terms of the collaboration were not disclosed.

"Our partnership with HUPO enables our researchers to work closely with thought leaders in the field of proteomics," explained Gregory T. Lucier, Chairman and CEO of Invitrogen Corporation. "By improving education, training and technology development, our organization can provide scientists the ability to better understand critically important areas of research."

By collaborating with leading protein laboratories internationally, Invitrogen and HUPO plan to foster a set of industry standards to enable large scale data generation and analysis, consistent with HUPO's mandate to shape the next phase of disease research and drug discovery. HUPO's Education and Training Initiative offers programs to promote expertise in all areas of proteomics including sample preparation, protein separation, mass spectrometry, bioinformatics and experimental design.

"This is a great opportunity for HUPO and all its members to acquire and set standards that will become applicable world-wide," said Prof. John J.M. Bergeron, President of HUPO. "This standardization effort, which is one of several that HUPO is spear-heading, is a major part of our organization's mission, and will act as a major impetus to the implementation of world-wide proteomic standards."

"The potential for improving the effectiveness of proteomics research is an extremely exciting part of our collaboration with HUPO," concluded Dr. Norrie Russell, Chief Scientific Officer for Invitrogen. "By adding our strength in technology development to the many other groups supporting HUPO's initiatives, we feel we can help proteomics realize its full potential in life sciences research."

Invitrogen has already developed a comprehensive technology portfolio for proteomic research. Highlighted by systems such as its ZOOM(R) Benchtop Proteomics(TM) fractionation and electrophoresis products, SILAC(TM) mass spectrometry reagents and its flagship ProtoArray(TM) protein microarray, the company has introduced several innovative platforms as a part of its extensive offerings.

For more information about Invitrogen's proteomics efforts, visit www.invitrogen.com/proteomics.

About Invitrogen Corporation

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of more than $1.2 billion in 2005. For more information, visit www.invitrogen.com.

About HUPO

The Human Proteome Organisation (HUPO) is an international consortium of national proteomics research associations, government researchers, academic institutions and industry partners. HUPO promotes the development and awareness of proteomics research, advocates on behalf of proteomics researchers throughout the world and facilitates scientific collaborations between HUPO members and Initiatives. For more information, visit www.hupo.org.

Safe Harbor Statement

Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to: 1) Invitrogen scientists will support HUPO efforts in education, standardization and product and process development; 2) Invitrogen and HUPO will create a set of industry standards for data generation and analysis; 3) Invitrogen's collaboration with HUPO will enable proteomics to realize its full potential in life sciences research. Potential risks and uncertainties include, but are not limited to, the risks: a) Invitrogen's participation in the collaboration is subject to change; b) Invitrogen and HUPO may not fully develop a set of industry standards for proteomics; c) Invitrogen and HUPO's collaboration may have no significant impact on proteomics research, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.